RT Journal Article
SR Electronic
T1 Clinical Outcomes and Prognostic Factors of Patients With Esophageal Squamous Cell Carcinoma With Oligo-recurrence Treated With Radical Re-irradiation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2387
OP 2392
DO 10.21873/anticanres.14208
VO 40
IS 4
A1 LIN, CHEN-YUAN
A1 FANG, HSIN-YUAN
A1 LEIN, MING-YU
A1 LIN, CHING-CHAN
A1 BAI, LI-YUAN
A1 TSAI, MING-HUNG
A1 CHEN, CHI-CHING
A1 HSIEH, TE-CHUN
A1 WANG, YAO-CHING
A1 LIANG, JI-AN
A1 LI, CHIA-CHIN
A1 CHIEN, CHUN-RU
YR 2020
UL http://ar.iiarjournals.org/content/40/4/2387.abstract
AB Background: For patients with esophageal squamous cell carcinoma (ESCC) with oligo-recurrence (OR) after previous curative radiotherapy and not eligible for radical resection, the role of radical re-irradiation was not clear. Therefore, we aimed to investigate the outcome and prognostic factors of such patients. Patients and Methods: We identified patients with OR of ESCC after previous curative radiotherapy and were treated with radical re-irradiation within 2012-2018 via an in-house prospectively established database. The characteristics of patients, disease, treatment, and outcome were retrospectively obtained via chart review. The first day of re-irradiation was defined as the index date. Overall survival was calculated via the Kaplan–Meier method. Log-rank test was used for univariate analysis and Cox regression method was used for multivariable analysis. Results: We identified thirty patients for analyses. After a median follow-up of 9 (range=2-76) months, the 5-year overall survival rate was 21%. Four patients with possible radiotherapy-related complication in need of inpatient care were identified. Gross tumor volume was the only significant prognostic factor in both univariate and multivariable analyses. Conclusion: We found that radical definitive re-irradiation may lead to one-fifth long-term survivors of patients with OR after previous curative radiotherapy for ESCC, and the gross tumor volume was the only significant prognostic factor for these patients. Randomized controlled trials should be considered to compare radical re-irradiation with the current standard of care (systemic therapy) for this population.